Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 37,413 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 37,413 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $0.55, for a total transaction of $20,577.15. Following the completion of the transaction, the director directly owned 2,198,642 shares in the company, valued at $1,209,253.10. This trade represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Wednesday, January 14th, Luke Evnin sold 30,616 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total transaction of $17,451.12.
• On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total transaction of $23,758.90.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock traded down $0.03 during trading on Thursday, reaching $0.55. The company’s stock had a trading volume of 663,533 shares, compared to its average volume of 489,381. The company has a 50-day moving average price of $0.85 and a two-hundred day moving average price of $1.24. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.38. The firm has a market cap of $26.74 million, a PE ratio of -0.34 and a beta of 0.77. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Several hedge funds have recently modified their holdings of HOWL. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Citadel Advisors LLC acquired a new stake in Werewolf Therapeutics in the third quarter valued at $304,000. Vanguard Group Inc. lifted its holdings in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares during the period. Marshall Wace LLP purchased a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $113,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Werewolf Therapeutics during the 2nd quarter worth $92,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HOWL has been the topic of several recent research reports. Wedbush cut Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Friday, December 19th. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Bank of America decreased their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Finally, Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Hold” and an average target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.